Viking Therapeutics (FRA:1VT) Net Income From Continuing Operations : €-119.17 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Viking Therapeutics's net income from continuing operations for the three months ended in Mar. 2025 was €-42.21 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-119.17 Mil.

Viking Therapeutics Net Income From Continuing Operations Historical Data

The historical data trend for Viking Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Net Income From Continuing Operations Chart

Viking Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-32.47

-48.67

-65.01

-78.77

-105.02

Viking Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-25.17	-20.67	-22.47	-33.82	-42.21

Viking Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-119.17 Mil.

Viking Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (FRA:1VT) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VKTX:Italy 0VQA:UK 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines